Research programme: metabolic disorder therapeutics - Energesis Pharmaceuticals

Drug Profile

Research programme: metabolic disorder therapeutics - Energesis Pharmaceuticals

Alternative Names: Brown adipose tissue stimulants - Energesis Pharmaceuticals; Brown fat stimulants - Energesis Pharmaceuticals; Brown fat-based therapeutics - Energesis Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Energesis Pharmaceuticals
  • Developer Energesis Pharmaceuticals; Janssen Pharmaceuticals
  • Class
  • Mechanism of Action Cell division stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Metabolic disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Metabolic-disorders in USA
  • 01 May 2014 Energesis Pharmaceuticals receives Phase I SBIR grant from National Institutes of Health for Metabolic disorder therapeutics
  • 01 Jun 2012 Energesis Pharmaceuticals receives Phase II STTR grant for Metabolic disorder therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top